Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Obexelimab - Zenas Biopharma

Next Previous
Drug Profile

Obexelimab - Zenas Biopharma

Alternative Names: AMG 729; Humanised Fc-engineered monoclonal antibody against CD19 - Xencor; XmAb® 5871

Latest Information Update: 12 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Developer Xencor; Zenas BioPharma
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; Fc gamma receptor IIB antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Immunoglobulin G4-related disease; Multiple sclerosis
  • Phase II Systemic lupus erythematosus
  • No development reported Autoimmune disorders
  • Discontinued Autoimmune haemolytic anaemia; Rheumatoid arthritis

Most Recent Events

  • 02 Feb 2025 Phase-II clinical trials in Multiple sclerosis (Treatment-experienced) in Austria, Belgium, China, Croatia, Czech Republic, Denmark, Greece, Italy, Poland, Spain, United Kingdom (SC) (NCT06564311)
  • 07 Jan 2025 Phase-II clinical trials in Systemic lupus erythematosus (Treatment-experienced) in Bulgaria, China, Germany, Greece, Japan, Italy, Poland, Portugal, Romania, Spain, Taiwan (SC) (NCT0655916)
  • 31 Dec 2024 Discontinued - Phase-II for Rheumatoid arthritis (Treatment-experienced) in Hungary, Czech Republic, Slovakia (IV) as of December 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top